Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update.
Advanced breast cancer
Antibody-drug conjugates
Erbb2
Systemic therapy
Tyrosin kinase inhibitors
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
12
07
2022
accepted:
10
08
2022
pubmed:
24
9
2022
medline:
29
10
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. For this consensus paper a total of eight scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.
Identifiants
pubmed: 36149495
doi: 10.1007/s00508-022-02082-3
pii: 10.1007/s00508-022-02082-3
pmc: PMC9606043
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-692Informations de copyright
© 2022. The Author(s).
Références
Bartsch R, Gampenrieder SP, Rinnerthaler G, et al. Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. Wien Klin Wochenschr. 2022;134(1/2):63–72.
pubmed: 35089396
pmcid: 8813714
Cortés J, Kim S, Chung W, et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. 2021;32:S1287–S8.
Hurvitz S, Kim S‑B, Chung W‑P, et al. Abstract GS3-01: trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Cancer Res. 2022;82(4_Supplement):GS3-01.
Batista MV, Cortez P, Ruiz M, et al. Abstract PD4-06: trastuzumab deruxtecan in patients with HER2 [+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study. Cancer Res. 2022;82(4_Supplement):PD4-06.
Curigliano G, Mueller V, Borges V, et al. Tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2021; https://doi.org/10.1016/j.annonc.2021.12.005 .
pubmed: 34954044
Manich CS, O’Shaughnessy J, Aftimos P, et al. LBA15 Primary outcome of the phase III SYD985. 002/TULIP trial comparing [vic-] trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol. 2021;32:S1288.
Petit T, Hajjaji N, Antoine E‑C, et al. Abstract P2-13-26: Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer (BC): First real-life data from the cohort temporary authorization for use (cATU) program in France. Cancer Res. 2022;82(4_Supplement):P2-13-26.
Bartsch R, Berghoff A, Furtner J, et al. 280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: results from the first stage of the phase II TUXEDO‑1 trial. Ann Oncol. 2021;32:S486.
DS-8201a versus T‑DM1 for human epidermal growth factor receptor 2 (HER2)-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and taxane DESTINY-breast03. https://ClinicalTrials.gov/show/NCT03529110 .
Europäische Arzneimittelagentur. Trastuzumab-Deruxtecan. 2021.
Mueller V, Wardley A, Paplomata E, et al. Preservation of quality of life in patients with human epidermal growth factor receptor 2—positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). Eur J Cancer. 2021;153:223–33.
pubmed: 34214937
A study of tucatinib or placebo with trastuzumab and pertuzumab for metastatic HER2+ breast cancer. https://ClinicalTrials.gov/show/NCT05132582 .
Hurvitz S, Harbeck N, Vahdat L, et al. 126TiP HER2CLIMB-02: Tucatinib or placebo with T‑DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. Ann Oncol. 2021;32:S75.
Gennari A, André F, Barrios C, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95.
pubmed: 34678411
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49.
pubmed: 32979513
Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452–78.
pubmed: 32259783
Swain SM, Miles D, Kim S‑B, et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol. 2019;37(15):1020.
Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610.
pubmed: 32468955
pmcid: 7403000
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.
pubmed: 31825569
European Medicines Agency. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine [press release. 2020.
Una Cidon E, Alonso P, Hickish T. Sensitivity and specificity of DPD deficiency screening test to predict capecitabine serious toxicities. Ann Oncol. 2017;28:iii119–iii20.
Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome. 2020. https://www.ago-online.de/ .
Extra JM, Antoine EC, Vincent-Salomon A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist. 2010;15(8):799–809.
pubmed: 20671105
pmcid: 3228018
Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast. 2013;22(Suppl 2):S152–S5.
pubmed: 24074778
von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2‑positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27(12):1999–2006.
von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3‑05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47(15):2273–81.
Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2‑positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–35.
pubmed: 30106636
Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111–10114): an open-label, randomised, phase 2 trial from the elderly task force/breast cancer group. Lancet Oncol. 2018;19(3):323–36.
pubmed: 29433963
Andersson M, López-Vega JM, Petit T, et al. Efficacy and safety of pertuzumab and trastuzumab administered in a single infusion bag, followed by vinorelbine: VELVET cohort 2 final results. Oncologist. 2017;22(10):1160–8.
pubmed: 28592618
pmcid: 5634765
Perez EA, López-Vega JM, Petit T, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results. Breast Cancer Res. 2016;18(1):126.
pubmed: 27955684
pmcid: 5154110
Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–42.
pubmed: 28526536
pmcid: 5531181
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–30.
pubmed: 20124187
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.
pubmed: 17192538
Johnston S, Pippen J Jr., Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.
pubmed: 19786658
Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol. 2021;39(1):79–89.
pubmed: 32822287
Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with 〉/= 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–49.
pubmed: 32678716
pmcid: 7499616
Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b‑2 trial. Lancet Oncol. 2019;20(3):371–82.
pubmed: 30765258
Tolaney SM, Wardley AM, Zambelli S, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763–75.
pubmed: 32353342
Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(7):880–8.
pubmed: 29804905